ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS PREVIOUSLY EXPOSED TO ANTI–TUMOR NECROSIS FACTOR AGENT: THE RANDOMIZED, PHASE 3 HICKORY TRIAL
Laurent Peyrin-Biroulet 1
1 Nancy University Hospital Inserm U954 Dept. of Hepato-Gastroenterology
Conference
UEG Week Virtual 2020
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]
New to myUEG?
Social Sharing